Long‐term outcomes among 2‐year survivors of autologous hematopoietic cell transplantation for Hodgkin and diffuse large b‐cell lymphoma. Issue 4 (10th November 2017)

• Record Type: Journal Article
• Authors: Myers, Regina M.; Hill, Brian T.; Shaw, Bronwen E.; Kim, Soyoung; Millard, Heather R.; Battiwalla, Minoo; Majhail, Navneet S.; Buchbinder, David; Lazarus, Hillard M.; Savani, Bipin N.; Flowers, Mary E. D.; D'Souza, Anita; Ehrhardt, Matthew J.; Langston, Amelia; Yared, Jean A.; Hayashi, Robert J.; Daly, Andrew; Olsson, Richard F.; Inamoto, Yoshihiro; Malone, Adriana K.; DeFilipp, Zachariah; Margossian, Steven P.; Warwick, Anne B.; Jaglowski, Samantha; Beitinjaneh, Amer; Fung, Henry; Kasow, Kimberly A.; Marks, David I.; Reynolds, Jana; Stockerl‐Goldstein, Keith; Wirk, Baldeep; Wood, William A.; Hamadani, Mehdi; Satwani, Prakash;
• Is Part Of: Cancer. Volume 124:Issue 4(2018)
• Page Start: 816
• Page End: 825
• Publication Date: 2017-11-10
• Subjects: autologous hematopoietic cell transplant -- diffuse large B‐cell lymphoma -- Hodgkin lymphoma -- late effects -- nonrelapse mortality -- survival; Cancer -- Periodicals; Cancer -- Cytopathology -- Periodicals; 616.99405
• DOI: 10.1002/cncr.31114
• Languages: English
• ISSNs: 0008-543X

Abstract

Abstract : BACKGROUND: Autologous hematopoietic cell transplantation (auto‐HCT) is a standard therapy for relapsed classic Hodgkin lymphoma (cHL) and diffuse large B‐cell lymphoma (DLBCL); however, long‐term outcomes are not well described. METHODS: This study analyzed survival, nonrelapse mortality, late effects, and subsequent malignant neoplasms (SMNs) in 1617 patients who survived progression‐free for ≥2 years after auto‐HCT for cHL or DLBCL between 1990 and 2008. The median age at auto‐HCT was 40 years; the median follow‐up was 10.6 years. RESULTS: The 5‐year overall survival rate was 90% (95% confidence interval [CI], 87%‐92%) for patients with cHL and 89% (95% CI, 87%‐91%) for patients with DLBCL. The risk of late mortality in comparison with the general population was 9.6‐fold higher for patients with cHL (standardized mortality ratio [SMR], 9.6) and 3.4‐fold higher for patients with DLBCL (SMR, 3.4). Relapse accounted for 44% of late deaths. At least 1 late effect was reported for 9% of the patients. A total of 105 SMNs were confirmed: 44 in the cHL group and 61 in the DLBCL group. According to a multivariate analysis, older age, male sex, a Karnofsky score < 90, total body irradiation (TBI) exposure, and a higher number of lines of chemotherapy before auto‐HCT were risk factors for overall mortality in cHL. Risk factors in DLBCL were older age and TBI exposure. A subanalysis of 798 adolescent and young adult patients mirrored the outcomes of the overall study population. CONCLUSIONS: Despite generally favorable outcomes, 2‐year survivors of auto‐HCT for cHL or DLBCL have an excess late‐mortality risk in comparison with the general population and experience an assortment of late complications. Cancer 2018;124:816‐25 . © 2017 American Cancer Society . Abstract : In a large multicenter cohort of 2‐year progression‐free survivors of autologous hematopoietic cell transplantation for Hodgkin and diffuse large B‐cell lymphoma, long‐term outcomes are favorable. Survivors, however, have an excess risk of late mortality in comparison with an age‐ and sex‐matched general population, and they experience a myriad of subsequent malignant neoplasms and nonmalignant late effects.